Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00185653 · ClinicalTrials.gov registry record · NA

Mixed Chimera Allogeneic Transplantation From Matched Unrelated Donors For The Treatment Of Multiple Myeloma

A NA study of Multiple Myeloma, sponsored by Stanford University.

Completed
Registry status
NA
Development phase
40
Enrollment target
1
Study location

NCT00185653: Completed NA study of Multiple Myeloma, sponsored by Stanford University.

NCT00185653 is a NA study of Multiple Myeloma that has completed, run by Stanford University. The registered enrollment target is 40 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00185653, a NA study of Multiple Myeloma, has completed, sponsored by Stanford University.

COMPLETED
Registry status
NA
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study is to determine the toxicity and feasibility of non-myeloablative allogeneic hematopoietic cell transplants for multiple myeloma from unrelated donors.

Conditions Studied

Interventions

  • PROCEDURE Autologous followed by non-myeloablative allogeneic transplantation

Study Locations (1)

California

  • Stanford University School of Medicine - Stanford

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2000-10
Est. Completion 2008-11
Phase NA
Stanford University

1,744 total trials

What the finished NCT00185653 record still lists

NCT00185653 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (93% lower).

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Autologous followed by non-myeloablative allogeneic transplantation is the first listed.

NCT00185653 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT00185653 about?

NCT00185653 is a clinical study titled "Mixed Chimera Allogeneic Transplantation From Matched Unrelated Donors For The Treatment Of Multiple Myeloma". The purpose of the study is to determine the toxicity and feasibility of non-myeloablative allogeneic hematopoietic cell transplants for multiple myeloma from unrelated donors.

What is the current status of trial NCT00185653?

This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2000-10. Estimated completion is 2008-11.

What conditions does trial NCT00185653 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT00185653?

The interventions under investigation include: Autologous followed by non-myeloablative allogeneic transplantation (PROCEDURE).

Who is sponsoring clinical trial NCT00185653?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00185653 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00185653's enrollment target sits among peer trials

40 289th of 438 higher than 135 of 438 other Multiple Myeloma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00185653, the US trial registry maintained by the National Library of Medicine. NCT00185653 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.